Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Angiotensin II

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Gland Pharma's Generic Angiotensin II Receives Approval in the U.S.
    Gland Pharma's Generic Angiotensin II Receives Approval in the U.S.

    14 Nov 2023

    // EMA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216966

    EMA
    14 Nov 2023
    Share Share
    FDA Confirms Paragraph IV Patent Litigation for Angiotensin II Acetate
    FDA Confirms Paragraph IV Patent Litigation for Angiotensin II Acetate

    09 Feb 2022

    // FDA

    https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-angiotensin-ii-acetate-1646027830.pdf

    FDA
    09 Feb 2022
    Share Share
    AZ bags two extensions in latest CHMP decisions
    AZ bags two extensions in latest CHMP decisions

    01 Jul 2019

    // Anna Smith PHARMATIMES

    http://www.pharmatimes.com/news/az_bags_two_extensions_in_latest_chmp_decisions_1292946

    Anna Smith PHARMATIMES
    01 Jul 2019
    Share Share
    La Jolla grabs $125M royalty deal to back drug launch, fund R&D
    La Jolla grabs $125M royalty deal to back drug launch, fund R&D

    12 May 2018

    // John Carroll ENDPTS

    https://endpts.com/la-jolla-grabs-125m-royalty-deal-to-back-drug-launch-fund-rd/

    John Carroll ENDPTS
    12 May 2018
    Share Share
    FDA approves drug to treat dangerously low blood pressure
    FDA approves drug to treat dangerously low blood pressure

    22 Dec 2017

    // BIOSPECTRUM

    https://www.biospectrumasia.com/news/25/10043/fda-approves-drug-to-treat-dangerously-low-blood-pressure.html

    BIOSPECTRUM
    22 Dec 2017
    Share Share